Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Mirati Therapeutics (NQ: MRTX)
102.62 USD  -2.18 (-2.08%)
Official Closing Price  /  Updated: 5:22 PM EST, Dec 6, 2019  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 538,900
Open 105.40
Bid (Size) 102.51 (8)
Ask (Size) 102.62 (21)
Prev. Close 104.80
Today's Range 101.57 - 109.74
52wk Range 34.39 - 111.99
Shares Outstanding 32,214,631
Dividend Yield N/A
Performance
YTD
+129.83%
+129.83%
1 Month
+4.71%
+4.71%
3 Month
+24.09%
+24.09%
6 Month
+1.88%
+1.88%
1 Year
+162.32%
+162.32%
Top News
More News
Mirati Therapeutics Presents Data From Ongoing Clinical Trials Of Sitravatinib In Combination With Nivolumab At The SITC 34th Annual Meeting
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, today announced the presentation of initial data from its ongoing Phase 2 clinical trial of sitravatinib in... Read More
from PR Newswire
Mirati Therapeutics Reports Third Quarter 2019 Financial Results
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the third quarter ended September 30, 2019. Read More
from PR Newswire
More News
Read More
AstraZeneca CEO: Closing In On A Cancer Cure
category AZN , General , CELG , and 11 more.
from Benzinga
Mirati Therapeutics Presents First Clinical Data Of Phase 1/2 Trial Of MRTX849 At The 2019 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics
from PR Newswire
Noteworthy Friday Option Activity: MRTX, DHR, AXE
category Stocks
from Market News Video
Noteworthy Tuesday Option Activity: MRTX, R, GPRE
category Stocks
from Market News Video
3 Cancer Treatment Stocks to Buy Right Now
category Market News , AMGN , PSNL , and 3 more.
from Motley Fool
Mid-Afternoon Market Update: Athenex Shares Spike; Grubhub Nosedives On Earnings Miss
category BYND , GRUB , Earnings , and 16 more.
from Benzinga
Better Buy: Mirati Therapeutics vs. Amgen
category MRTX , AMGN , Market News , and 1 more.
from Motley Fool
Mid-Morning Market Update: Markets Mixed; General Motors Profit Beats Views
category Global , Markets , DBD , and 16 more.
from Benzinga
Can This Tiny Biotech Take Down Amgen?
category Market News , AMGN , MRTX
from Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.